According to CoinMeta, at the third-quarter performance briefing in 2026, Hengtong Co., Ltd. stated that the company will build on its existing business to continuously promote internal collaboration and resource integration within its biotechnology business segment, fully leveraging synergies to enhance the overall competitiveness of its current product lines. In addition, the company will also actively monitor technological and product opportunities in external niche areas, conduct prudent evaluations around key links in the industrial chain and emerging technology directions, and seize opportunitiesto improve its industrial layout through cooperation, investment, and other means.